These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 23728349

  • 1. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
    Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, Park E, Naing K, Klemm L, Swaminathan S, Conway EM, Pelus LM, Crispino J, Mullighan CG, McMillan M, Müschen M, Kahn M, Kim YM.
    Oncogene; 2014 Apr 24; 33(17):2169-78. PubMed ID: 23728349
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression.
    Ma H, Nguyen C, Lee KS, Kahn M.
    Oncogene; 2005 May 19; 24(22):3619-31. PubMed ID: 15782138
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL.
    Cancer Lett; 2016 Oct 10; 381(1):58-66. PubMed ID: 27431312
    [Abstract] [Full Text] [Related]

  • 10. Wnt/β-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours.
    Wend P, Fang L, Zhu Q, Schipper JH, Loddenkemper C, Kosel F, Brinkmann V, Eckert K, Hindersin S, Holland JD, Lehr S, Kahn M, Ziebold U, Birchmeier W.
    EMBO J; 2013 Jul 17; 32(14):1977-89. PubMed ID: 23736260
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
    Yamada K, Hori Y, Inoue S, Yamamoto Y, Iso K, Kamiyama H, Yamaguchi A, Kimura T, Uesugi M, Ito J, Matsuki M, Nakamoto K, Harada H, Yoneda N, Takemura A, Kushida I, Wakayama N, Kubara K, Kato Y, Semba T, Yokoi A, Matsukura M, Odagami T, Iwata M, Tsuruoka A, Uenaka T, Matsui J, Matsushima T, Nomoto K, Kouji H, Owa T, Funahashi Y, Ozawa Y.
    Cancer Res; 2021 Feb 15; 81(4):1052-1062. PubMed ID: 33408116
    [Abstract] [Full Text] [Related]

  • 18. ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population.
    Liu Y, Chen H, Zheng P, Zheng Y, Luo Q, Xie G, Ma Y, Shen L.
    J Exp Clin Cancer Res; 2017 Sep 11; 36(1):125. PubMed ID: 28893318
    [Abstract] [Full Text] [Related]

  • 19. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth.
    Arensman MD, Telesca D, Lay AR, Kershaw KM, Wu N, Donahue TR, Dawson DW.
    Mol Cancer Ther; 2014 Oct 11; 13(10):2303-14. PubMed ID: 25082960
    [Abstract] [Full Text] [Related]

  • 20. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
    Zhao Y, Wu K, Wu Y, Melendez E, Smbatyan G, Massiello D, Kahn M.
    Curr Mol Pharmacol; 2018 Oct 11; 11(2):113-121. PubMed ID: 28933312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.